Drug intelligence / Profile preview

eflimrufusp alfa

Development stage: Phase 3
Lead developer: RemeGen
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Ophthalmic

Overview

Eflimrufusp alfa (RC28-E) is a recombinant fusion protein biologic developed by RemeGen Co., Ltd. It is designed as a dual-targeting decoy receptor trap that simultaneously inhibits Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth Factor 2 (FGF2). By blocking both pathways, it aims to address the complex pathophysiology of retinal vascular diseases more effectively than traditional anti-VEGF monotherapies. The drug is currently being evaluated in clinical trials for various ophthalmic conditions, including nonproliferative diabetic retinopathy (NPDR), wet age-related macular degeneration (wAMD), and diabetic macular edema (DME). It is administered via intravitreal injection to directly target the ocular environment.

Other names: eflimrufusp alfa

Targets

VEGFA (Vascular endothelial growth factor A)FGF2

Beyond the preview

Go deeper on eflimrufusp alfa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eflimrufusp alfa.

Explore the full profile